Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.
Show others and affiliations
2018 (English)In: Neoplasia, ISSN 1522-8002, E-ISSN 1476-5586, Vol. 20, no 1, p. 25-31Article in journal (Refereed) Published
Abstract [en]

Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of less than 15 months, emphasizing the need for better treatments. Immunotherapy as a treatment for improving or aiding the patient's own immune defense to target the tumor has been suggested for GBM. A randomized clinical trial of adoptive cell transfer using ALECSAT (Autologous Lymphoid Effector Cells Specific Against Tumor Cells) is currently ongoing in Sweden. Here we performed a paired pre-clinical study to investigate the composition and in vitro effect of ALECSAT and identify determinants for the effect using autologous GBM-derived cancer stem cells (CSC), immunocytochemistry and flow cytometry. We show a clear dose-response relationship of ALECSAT on CSC, suggesting that the number of infused cells is of importance. In addition, the in vitro effect of ALECSAT on CSC correlated significantly to the blood count of T helper (Th) cells in the patient indicating a potential benefit of collecting cells for ALECSAT preparation at an even earlier stage when patients generally have a better blood count. The factors identified in this study will be important to consider in the design of future immunotherapy trials to achieve prolonged survival.

Place, publisher, year, edition, pages
2018. Vol. 20, no 1, p. 25-31
National Category
Basic Medicine
Identifiers
URN: urn:nbn:se:uu:diva-335343DOI: 10.1016/j.neo.2017.10.006ISI: 000418566000003PubMedID: 29190492OAI: oai:DiVA.org:uu-335343DiVA, id: diva2:1162461
Funder
Swedish Cancer SocietySwedish Research CouncilSwedish Society for Medical Research (SSMF)Wenner-Gren FoundationsAFA Insurance
Available from: 2017-12-04 Created: 2017-12-04 Last updated: 2018-01-25Bibliographically approved

Open Access in DiVA

fulltext(1062 kB)3 downloads
File information
File name FULLTEXT01.pdfFile size 1062 kBChecksum SHA-512
95086d38b76f3d331462c28193a01f0b0e619da9cbb849f18916da4c807c8fe946f431f6ca3322d020226aa6462842af689633ada684f620639ea7338533b261
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Smits, Anja
By organisation
Neurology
In the same journal
Neoplasia
Basic Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 3 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 43 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf